| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.028 |
| 52 Week High | SEK 0.82 |
| 52 Week Low | SEK 0.026 |
| Beta | 0.50 |
| 11 Month Change | -18.95% |
| 3 Month Change | -68.48% |
| 1 Year Change | -88.95% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIABIO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -10.0% | 2.6% | -0.4% |
| 1Y | -88.9% | 14.4% | 12.9% |
Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned 14.4% over the past year.
Return vs Market: DIABIO underperformed the Swedish Market which returned 12.9% over the past year.
Price Volatility
| DIABIO volatility | |
|---|---|
| DIABIO Average Weekly Movement | 28.6% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: DIABIO's share price has been volatile over the past 3 months.
Volatility Over Time: DIABIO's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
| DIABIO fundamental statistics | |
|---|---|
| Market cap | SEK 11.14m |
| Earnings (TTM) | -SEK 10.97m |
| Revenue (TTM) | SEK 2.37m |
4.7x
P/S Ratio-1.0x
P/E RatioIs DIABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIABIO income statement (TTM) | |
|---|---|
| Revenue | SEK 2.37m |
| Cost of Revenue | SEK 18.00k |
| Gross Profit | SEK 2.35m |
| Other Expenses | SEK 13.33m |
| Earnings | -SEK 10.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 99.24% |
| Net Profit Margin | -462.88% |
| Debt/Equity Ratio | 0% |
How did DIABIO perform over the long term?
See historical performance and comparison